Metoclopramide

Gastroparesis, Aerophagy, Migraine + 23 more
Treatment
4 FDA approvals
20 Active Studies for Metoclopramide

What is Metoclopramide

MetoclopramideThe Generic name of this drug
Treatment SummaryMetoclopramide is a medication used to treat nausea, vomiting, and other symptoms caused by diabetic gastroparesis. It is also used to treat nausea and vomiting caused by chemotherapy or certain medical procedures. Unlike some other medications, metoclopramide does not increase stomach acid production. It comes in tablet and liquid form and can also be given intravenously. Metoclopramide was first approved by the FDA in 1980.
Metoclopramideis the brand name
image of different drug pills on a surface
Metoclopramide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Metoclopramide
Metoclopramide
1985
199

Approved as Treatment by the FDA

Metoclopramide, commonly known as Metoclopramide, is approved by the FDA for 4 uses including Gastroesophageal reflux disease and Gastroesophageal Reflux Disease (GERD) .
Gastroesophageal reflux disease
Gastroesophageal Reflux Disease (GERD)
Failed conventional therapy
Gastroparesis

Effectiveness

How Metoclopramide Affects PatientsMetoclopramide helps food pass through your digestive system by reducing the pressure of the lower esophageal sphincter. It also helps prevent and reduce symptoms of nausea and vomiting. It increases digestive activity without increasing the amount of acid produced in the stomach, bile, or pancreas. However, it should not be taken for longer than 12 weeks since it can cause tardive dyskinesia (TD), dystonia, and akathisia.
How Metoclopramide works in the bodyMetoclopramide works to prevent nausea and vomiting by blocking dopamine and serotonin receptors in the brain. It also increases the amount of acetylcholine released, which helps to speed up digestion and reduce stomach discomfort. Metoclopramide also works by blocking dopamine receptors, which can help to relax the gastrointestinal tract.

When to interrupt dosage

The prescribed measure of Metoclopramide is reliant upon the identified illness, including Nausea, Intubation (process) and Gastroesophageal Reflux Disease (GERD). The dosage may differ, as indicated by the administration technique (e.g. Spray or Tablet, orally disintegrating) listed in the table beneath.
Condition
Dosage
Administration
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
gastric emptying for radiologic procedures
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Therapeutic procedure
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Gastric Motility Disorder
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
prophylaxis of Hiccups
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
meteorism
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Failed conventional therapy
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Acute Coryza
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Hyperacidity
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
radiation therapy induced nausea and vomiting
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Aerophagy
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Flatulence
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Indigestion
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Gastrointestinal distress
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Hiccup
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Nausea
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Pharmacotherapy
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous
Intubation (procedure)
10.0 mg, , 5.0 mg, 5.0 mg/mL, 10.0 mg/mL, 1.0 mg/mL, 1.0 mg, 9.0 mg/mL, 1500.0 mg/mL
, Oral, Tablet, Tablet - Oral, Solution, Solution - Oral, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, solution, Injection, solution - Intramuscular; Intravenous, Intravenous, Injection - Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Syrup, Syrup - Oral, Liquid - Oral, Liquid - Intravenous, Injection, solution - Intravenous, Kit - Oral; Topical, Kit, Oral; Topical, Nasal, Spray, Spray - Nasal, Solution - Intramuscular; Intravenous

Warnings

Metoclopramide Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Metoclopramide may interact with Pulse Frequency
Mechanical Intestinal Obstruction
Do Not Combine
Gastrointestinal Hemorrhage
Do Not Combine
Gastrointestinal Perforation
Do Not Combine
Paraganglioma
Do Not Combine
Tardive Dyskinesia
Do Not Combine
Pharmaceutical Preparations
Do Not Combine
Pheochromocytoma
Do Not Combine
Parkinson's Disease
Do Not Combine
Depression
Do Not Combine
Epilepsy
Do Not Combine
Gastrectomy
Do Not Combine
Dystonia
Do Not Combine
Feeling suicidal (finding)
Do Not Combine
There are 20 known major drug interactions with Metoclopramide.
Common Metoclopramide Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.
Aceprometazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aceprometazine.
Acetophenazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.
Alimemazine
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Alimemazine.
Amisulpride
Major
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.
Metoclopramide Toxicity & Overdose RiskMetoclopramide has a toxic dose of 750mg/kg in rats. An overdose on metoclopramide can cause drowsiness, confusion, and muscle control problems. To treat these symptoms, drugs used for Parkinson's disease or antihistamines with anticholinergic properties may be used. In some cases, these symptoms may last up to 24 hours. Unintentional overdose in infants can lead to seizures, muscle control issues, and a weak state. Additionally, methemoglobinemia (a rare blood disorder) can occur after an overdose. To treat this, methylene blue may be administered. However
image of a doctor in a lab doing drug, clinical research

Metoclopramide Novel Uses: Which Conditions Have a Clinical Trial Featuring Metoclopramide?

113 active clinical trials are presently evaluating the potential of Metoclopramide to alleviate Migraine, Nausea and as an adjunct in Pharmacotherapy.
Condition
Clinical Trials
Trial Phases
Gastroparesis
15 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Early Phase 1
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Gastric Acid
0 Actively Recruiting
Gastroesophageal Reflux Disease (GERD)
9 Actively Recruiting
Not Applicable, Phase 2
Flatulence
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Indigestion
6 Actively Recruiting
Phase 3, Not Applicable, Phase 2
radiation therapy induced nausea and vomiting
0 Actively Recruiting
Nausea
0 Actively Recruiting
Gastrointestinal distress
9 Actively Recruiting
Phase 2, Early Phase 1, Phase 1, Phase 3, Not Applicable, Phase 4
Hiccup
0 Actively Recruiting
Failed conventional therapy
0 Actively Recruiting
meteorism
0 Actively Recruiting
Nausea
0 Actively Recruiting
Gastric Motility Disorder
0 Actively Recruiting
Aerophagy
0 Actively Recruiting
Intubation (procedure)
0 Actively Recruiting
gastric emptying for radiologic procedures
0 Actively Recruiting
prophylaxis of Hiccups
0 Actively Recruiting

Metoclopramide Reviews: What are patients saying about Metoclopramide?

5Patient Review
6/13/2017
Metoclopramide for Condition in which Stomach Acid is Pushed Into the Esophagus
I've been taking this medication for nearly a decade, and have only just now realized that it has caused my breasts to grow larger and my sex drive to dwindle. As a man, this was never explained to me by the doctor prescribing the drug, and I feel like it amounts to criminal negligence.
4.7Patient Review
1/19/2017
Metoclopramide for Condition in which Stomach Acid is Pushed Into the Esophagus
I had great results for the three weeks I took this medication. It stopped my acid reflux and helped slow my diarrhea, but now the pharmacy says I can't renew it.
4Patient Review
12/4/2019
Metoclopramide for Condition in which Stomach Acid is Pushed Into the Esophagus
I've been on this medication for a while now and it seems to be helping, though I am concerned about how long I've been taking it. From what I can tell, it's supposed to be temporary.
3Patient Review
2/2/2019
Metoclopramide for Nausea and Vomiting
I was prescribed this to help with pregnancy-related nausea and vomiting. It worked for two days, at which point I stopped taking it due to the deep all-day migraine it caused, as well as toothache pain.
2.7Patient Review
10/21/2021
Metoclopramide for Condition in which Stomach Acid is Pushed Into the Esophagus
I felt incredibly drowsy after taking this drug, to the point where I couldn't speak properly. My stomach also felt empty and I was overall quite tired.
2.3Patient Review
3/21/2021
Metoclopramide for Condition in which Stomach Acid is Pushed Into the Esophagus
One significant downside to this medication is that it made me quite drowsy to the point where I was nodding off even while walking. It became difficult to stick to my usual routine. After a few days, I had to stop taking it.
2.3Patient Review
10/21/2021
Metoclopramide for Condition in which Stomach Acid is Pushed Into the Esophagus
I am taking the medication three times a day as prescribed. I have noticed increased drowsiness, difficulty speaking due to fatigue in my jaw, and a general feeling of emptiness in my stomach.
2.3Patient Review
6/7/2018
Metoclopramide for Nausea and Vomiting
Though it did stop my vomiting, I experienced an incredibly painful panic attack less than an hour later. This was the first and only time I've ever had a panic attack in my life.
2Patient Review
5/25/2022
Metoclopramide for Nausea and Vomiting
I had a really bad experience with this medication, to the point where it was affecting my vision. I would never take it again.
1.3Patient Review
7/4/2017
Metoclopramide for Stomach Muscle Paralysis and Decreased Function
I found that this treatment caused me a lot of trouble sleeping, agitation, and even thoughts of suicide. I was also very confused and felt quite depressed while taking it.
1Patient Review
7/21/2020
Metoclopramide for Nausea and Vomiting
I would not recommend this medication to anyone. I tried it and had an incredibly negative reaction. Within a day, I started feeling uncomfortable and by the end of the day, was hyperventilating, uncontrollably moving, and panicking. Do not take this drug.
1Patient Review
9/17/2019
Metoclopramide for Nausea and Vomiting
This drug had an unfortunate side effect of making me feel perpetually nauseous. It was prescribed to help with morning sickness during pregnancy, but all it did was make me more sick.
1Patient Review
7/2/2020
Metoclopramide for Nausea and Vomiting
I took this for nausea and it gave me incredibly bad anxiety, uncontrollable muscle movements, and made it impossible to sit still. Please be careful with this drug-- the side effects could become permanent if you take it for too long.
1Patient Review
8/13/2017
Metoclopramide for Nausea and Vomiting
The patient I was treating with this saw severe side effects after just two days of use. They are now dealing with Parkinson's-like symptoms and we haven't found any way to reverse the damage done.
1Patient Review
3/16/2017
Metoclopramide for Heartburn
The Restless Leg Syndrome got so bad that I couldn't sleep!
1Patient Review
11/7/2022
Metoclopramide for Stomach Muscle Paralysis and Decreased Function
I had terrible diarrhea and lost four pounds in the week that I took this medication. Additionally, it made everything outside look too bright and my vision felt different. As soon as I stopped taking the medication, these symptoms subsided.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about metoclopramide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is metoclopramide used for?

"Metoclopramide can help with nausea and vomiting caused by cancer treatment, migraines, or other conditions."

Answered by AI

Is metoclopramide the same as Zofran?

"The brand names for ondansetron are Zofran, Zofran ODT, and Zuplenz. The brand names for metoclopramide are Reglan and Metozolv ODT. Ondansetron and metoclopramide are in different drug classes. Ondansetron is an anti-nausea medication and metoclopramide is a "prokinetic" drug."

Answered by AI

What class of drugs is metoclopramide?

"Oct 15, 2018Metoclopramide belongs to a class of medications called prokinetic agents. It works by speeding up the movement of food through the stomach and intestines."

Answered by AI

What are the side effects of metoclopramide?

"The following effects may occur: drowsiness, dizziness, tiredness, trouble sleeping, agitation, headache, and diarrhea. If you experience any of these effects for an extended period of time, or if they get worse, tell your doctor or pharmacist."

Answered by AI

Clinical Trials for Metoclopramide

Image of Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada.

Aprepitant for Postoperative Nausea and Vomiting

18+
All Sexes
Montreal, Canada
Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.
Phase 3
Waitlist Available
Centre hospitalier de l'Université de Montréal (CHUM)Maxim Roy, MD, FRCPC
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of Endeavor Health in Evanston, United States.

Autonomic Neural Blockade for Postoperative Symptoms in Bariatric Surgery

18 - 90
All Sexes
Evanston, IL
The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain/nausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.
Waitlist Available
Has No Placebo
Endeavor HealthHerbert Hedberg, MD
Have you considered Metoclopramide clinical trials? We made a collection of clinical trials featuring Metoclopramide, we think they might fit your search criteria.Go to Trials
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Have you considered Metoclopramide clinical trials? We made a collection of clinical trials featuring Metoclopramide, we think they might fit your search criteria.Go to Trials
Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Phase 3
Waitlist Available
HCA Florida north florida HospitalRobyn Hoelle, MD
Image of The Hospital for Sick Children in Toronto, Canada.

ML-Based Intervention for Vomiting in Pediatric Cancer

Any Age
All Sexes
Toronto, Canada
The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients. The main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will: Primary 1\. Reduce the proportion with any vomiting within the 96-hour window Secondary 1. Reduce the number of vomiting episodes 2. Increase the proportion receiving care pathway-consistent care 3. Impact on number of administrations and costs of antiemetic medications Newly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.
Recruiting
Has No Placebo
The Hospital for Sick ChildrenSantiago Arciniegas, MSc
Have you considered Metoclopramide clinical trials? We made a collection of clinical trials featuring Metoclopramide, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security